Veracuity Blog The right drug at the right dose to the right patient: the value of pharmacogenomic information In April 2019, Mozilla internet health report published an article “23 reasons not to reveal your DNA” [1]. The primary reasons why people should worry about sharing their DNA with strangers are quite obvious – privacy concerns,…
Veracuity Blog Social media as a source of adverse drug effects People increasingly turn to online sources to search for health-related information, investigate options they have, and only then decide whether it is worth investing time and money to get the qualified opinion of a healthcare professional. Pew Research Center asked U.S. adults about their…
Veracuity Blog Digital epidemiology in pharmacovigilance One of the most important shortcomings of the current pharmacovigilance data collection system is the fact that the FDA Adverse Drug Event Reporting System (FAERS) does not provide any insight into the incidence, prevalence, and rates of occurrence of adverse drug events in the post-approval period [1]. To improve…
Veracuity Blog Pharmacovigilance at a crossroads The global pharmacovigilance market is growing and is still expected to grow. In 2013, post-market safety surveillance accounted for 60% of the global pharmacovigilance market and should reach $6 billion by 2020. Main drivers for increased reporting of adverse drug reactions include compliance requirements and liability resulting from high-profile…